MAIA Biotechnology, Inc. (MAIA): Total Assets

Annual figures by period end, from SEC filings.

$9.70M
As of 2025-12-31
$28.24M
As of 2026-06-30
-6.9%
3-year compound annual growth
$12.02M2021-12-31: $11.33M2022-12-31: $12.02M2023-12-31: $7.57M2024-12-31: $10.16M2025-12-31: $9.70M$9.70M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$9.70M-4.4%2026-03-23, Balance as of period end
2024-12-31$10.16M+34.2%2026-03-23, Balance as of period end
2023-12-31$7.57M-37.1%2025-03-21, Balance as of period end
2022-12-31$12.02M+6.1%2024-03-21, Balance as of period end
2021-12-31$11.33Mn/a2023-03-24, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
MAIA Biotechnology, Inc. (MAIA)2025-12-31$9.70M-4.4%
Cocrystal Pharma, Inc. (COCP)2025-12-31$9.71M-27.8%
FibroBiologics, Inc. (FBLG)2025-12-31$9.62M-41.5%
Can-Fite BioPharma Ltd. (CANF)2025-12-31$9.51M+4.3%
Kala Bio, Inc. (KALA)2025-12-31$9.49M-82.9%
Korsana Biosciences, Inc. (KRSA)2025-12-31$9.98M+4.3%
Medicus Pharma Ltd. (MDCX)2025-12-31$10.06M+78.2%
Oragenics Inc (OGEN)2025-12-31$10.07M+583.7%
Indaptus Therapeutics, Inc. (INDP)2025-12-31$9.31M+26.9%

Compare MAIA, COCP, FBLG, CANF side by side · Screen every company in Pharmaceutical Preparations ↗